These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 32372515)

  • 1. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
    Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States.
    Nyberg LM; Cheetham TC; Patton HM; Yang SJ; Chiang KM; Caparosa SL; Stern JA; Nyberg AH
    Hepatol Commun; 2021 Jan; 5(1):83-96. PubMed ID: 33437903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients.
    Kim Y; Medicis J; Davis M; Nunag D; Gish R
    Adv Ther; 2024 Nov; 41(11):4335-4355. PubMed ID: 39316292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
    C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
    Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease.
    De Luca-Johnson J; Wangensteen KJ; Hanson J; Krawitt E; Wilcox R
    Dig Dis Sci; 2016 Sep; 61(9):2710-20. PubMed ID: 27262844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Le MH; Le DM; Baez TC; Dang H; Nguyen VH; Lee K; Stave CD; Ito T; Wu Y; Yeo YH; Ji F; Cheung R; Nguyen MH
    Clin Mol Hepatol; 2024 Apr; 30(2):235-246. PubMed ID: 38281814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.